Bio-Gene Secures A$3.0M in U.S. Defense Grants for Insecticide Development

Bio-Gene Technology Ltd. ( (AU:BGT) ) has issued an announcement.

Bio-Gene Technology Ltd. has been awarded two grants totaling A$3.0 million from the U.S. Department of Defense’s Deployed Warfighter Protection program. These grants will support the development of innovative insect control products using Flavocide® and Qcide® targeting military and civilian markets. The funding enhances Bio-Gene’s industry positioning by validating its novel technology in the insecticide sector, potentially offering improved protection against disease-carrying pests for military personnel and the public.

More about Bio-Gene Technology Ltd.

Bio-Gene Technology Limited is an Australian company that focuses on developing new insecticides derived from nature. The company’s primary products include Flavocide® and Qcide®, which are aimed at achieving high impact in the insecticide market worldwide.

YTD Price Performance: -34.88%

Average Trading Volume: 82,478

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$5.64M

For an in-depth examination of BGT stock, go to TipRanks’ Stock Analysis page.